Veltarix for treating advanced non-small-cell lung cancer

Reference: GID-TA11218 · Expected publication date: 23 December 2026

1.1 Recommendation status

NICE is currently developing technology appraisal guidance on veltarix for treating advanced non-small-cell lung cancer in adults whose tumours express PD-L1 ≥ 50% and who have had no prior systemic therapy.

1.2 Decision problem

The decision problem has been agreed with NICE per the final scope.3 PICO questions have been consolidated. Submission deadline: 2026-09-01 (93 days remaining).

1.3 Evidence summary

Total requirements: 32
Met: 18
Gaps: 14
Blocker-severity gaps: 2

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their professional judgement.